Please login to the form below

Not currently logged in
Email:
Password:

Dr Gopalan Narayanan joins VCLS

He takes up a 'disruptive biologics' role at the product development consultancy

Product development consultancy Voisin Consulting Life Sciences has appointed Dr Gopalan Narayanan as vice president, disruptive biologics.

He brings over 18 years of experience as a pharmaceutical physician to the role, which will see him provide strategic advice to developers of complex biologics.

Dr Narayanan said: “Advanced therapy medicinal products present unique scientific and regulatory challenges requiring tailored solutions to fulfill their promise. I am delighted to be part of an organisation which is leading this very exciting future direction of medicine.”

With a focus on advanced therapies and other biologics, he was at UK medicines regulator the MHRA for nearly 12 years as an expert medical assessor and during that time spent four years as the head of its biologicals unit.

Founder and CEO of VCLS Dr Emmanuelle Voisin said: “The appointment of Dr Narayanan further enhances VCLS’s ability to support biotechnology companies throughout ATMP research and development, and lead scientific interactions with regulators and payers. Narayanan’s considerable experience strengthens our capabilities to provide clients with a global perspective, at the forefront of scientific innovation.”

In his new role, Dr Narayanan will deliver strategic direction, specifically in advanced therapy medicinal products, for the company.

14th March 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

Theodora Harold
A snapshot of Crescendo Biologics
PME talks to CEO Theodora Harold...
eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...

Infographics